Pharmaceutical & Health Packaging: Supplier Qualification Guide

Overview #

Qualifying a Chinese OEM supplier for pharmaceutical and health packaging is not the same as sourcing a cosmetic folding carton — the regulatory exposure is higher, the documentation trail is longer, and a single non-conformance can trigger a product recall or a customs hold. This guide covers the three stages where qualification decisions are made: factory audit, sample approval, and incoming QC at your warehouse or 3PL. It is most relevant to brands sourcing medicine cartons, nutraceutical folding boxes, OTC drug secondary packaging, and health supplement sleeves. The single most important thing we tell new pharmaceutical packaging partners: GMP-aligned production controls and print accuracy are not optional add-ons — they are built into our process from the first sample run.

---

Factory Audit Checklist: What to Verify Before You Place an Order #

When a pharmaceutical brand asks us to support a third-party audit or complete a supplier questionnaire, these are the parameters we expect to be assessed on — and the thresholds that matter.

Facility and process controls:

• Clean room or controlled environment for pharmaceutical carton production: particulate count should not exceed ISO Class 8 (ISO 14644-1) in the cutting and finishing area
• Temperature and humidity in the pressroom: we maintain 20–25°C and 45–60% RH to prevent board moisture uptake, which directly affects dimensional stability and crease performance
• Ink and coating systems: all inks used on pharmaceutical cartons must be low-migration, compliant with EuPIA Good Manufacturing Practice guidelines and, where food-contact adjacency applies, traceable to EU 10/2011 or FDA 21 CFR 175.300 indirect food contact standards
• Solvent residual limits: for water-based flexo and offset inks on medicine cartons, we target residual solvent levels below 5 mg/m² per individual solvent, consistent with Swiss Ordinance SR 817.023.21 limits used as a global benchmark

Documentation and traceability:

• Batch traceability records retained for minimum 3 years (aligned with EU GMP Annex 15 expectations for packaging materials)
• Certificate of Conformance (CoC) issued per production lot
• Ink and substrate supplier declarations available on request — we maintain these on file for all pharmaceutical-grade jobs

Print quality infrastructure:

• Inline spectrophotometric colour measurement: we run ΔE tolerances of ≤1.5 CIE Lab units against approved G7-calibrated proofs on all pharmaceutical carton lines
• 100% camera-based vision inspection for text legibility, barcode grade, and register accuracy — our register tolerance on sheet-fed offset is ±0.2mm, which is the threshold above which small-font dosage text becomes unreliable

---

Sample Approval Criteria: What We Require Before Production Sign-Off #

Sample approval for pharmaceutical packaging is a multi-gate process. We do not accept a single “looks good” email as approval — and we advise our brand partners not to either.

Structural and material verification:

• Substrate: pharmaceutical folding cartons typically specify SBS (Solid Bleached Sulphate) board at 270–350 gsm, or FBB (Folding Box Board) at 230–300 gsm. We specify SBS for direct-contact secondary packaging where whiteness and ink holdout are critical — SBS typically achieves CIE whiteness ≥ 105 and brightness ≥ 88% ISO
• Caliper tolerance: board caliper must be within ±5% of the specified value. For a 300 gsm SBS carton, that means caliper should fall between 370–410 µm. Boards outside this range cause feeding jams on high-speed cartoning lines running at 200–400 cartons/minute
• Crease and fold performance: we test crease recovery angle per TAPPI T556 — for pharmaceutical cartons, a crease recovery angle above 25° typically indicates under-creasing and will cause panel spring-back on auto-assembly lines
• Burst strength: minimum 400 kPa per ISO 2758 for standard medicine carton weights; we test every substrate lot on receipt

Print and finishing verification on samples:

• Barcode verification: all barcodes on pharmaceutical cartons must achieve minimum Grade B (ISO/IEC 15416) — we target Grade A on all production runs. A Grade C barcode will fail most pharmaceutical brand partner incoming QC scans
• Braille embossing: EU Directive 2004/27/EC requires Braille on all prescription medicine packaging sold in the EU. We verify Braille dot height at 0.2–0.5mm and dot spacing per EN ISO 17351 on every pharmaceutical sample
• Varnish and lamination: for pharmaceutical cartons, we specify UV-cured matte or gloss varnish at 4–6 g/m² coat weight. Aqueous coatings below 3 g/m² do not provide adequate scuff resistance for blister-pack cartoning line handling

---

Incoming QC Protocol: Numeric Thresholds for Receiving Inspection #

Once cartons arrive at your warehouse or 3PL, a documented incoming QC protocol protects you from running a non-conforming batch through your filling line. We provide the following guidance based on what we build into our own pre-shipment inspection.

Sampling plan:

• We recommend AQL 1.0 for critical defects (missing text, incorrect barcode, wrong Braille) and AQL 2.5 for major defects (colour shift, crease misalignment) per ANSI/ASQ Z1.4. For a shipment of 50,000 cartons, AQL 1.0 requires a sample of 200 units with zero critical defect acceptance
• Dimensional check: measure length, width, and depth of 30 cartons per lot. Reject the lot if more than 3 units fall outside ±0.5mm of the approved drawing dimension — this is the tolerance at which auto-cartoning line changeover becomes unreliable

Critical defect categories for pharmaceutical cartons:

• Any missing, illegible, or incorrect text (dosage, batch number placeholder, expiry window)
• Barcode below Grade B per ISO/IEC 15416
• Braille absent or dot height below 0.2mm
• Delamination or coating adhesion failure (cross-hatch tape test per ISO 2409, rating GT0 required)
• Colour ΔE > 3.0 CIE Lab units versus approved standard (ΔE > 1.5 is flagged as a minor deviation; > 3.0 triggers rejection)

---

Specification Notes for Brand Partners #

When you brief us on a pharmaceutical or health packaging project, the first documents we need are your artwork file (print-ready PDF/X-4 preferred), your structural dieline or reference carton dimensions, and your target market regulatory requirements — EU, US FDA, or ASEAN markets each carry different labelling and material compliance obligations.

The most common brief mistake we see is brands specifying a cosmetic-grade SBS board for a pharmaceutical carton without confirming the board supplier’s migration test data. Not all SBS is equivalent — we only approve substrate suppliers who can provide full migration testing documentation aligned with EU 10/2011 or equivalent.

Our standard pharmaceutical carton sampling process: digital colour proof in 3–5 working days, physical pre-production sample with Braille and barcode verification in 12–15 working days, production lead time 25–30 working days after written sample approval. All pharmaceutical jobs ship with a full CoC, substrate mill certificate, and ink compliance declaration.

---

Frequently Asked Questions #

Q1: What board weight do you recommend for a standard OTC medicine carton, and why does it affect our cartoning line?
A: For most OTC medicine cartons, we specify SBS board at 270–300 gsm. Below 270 gsm, panel rigidity drops and cartons tend to collapse under the compression fingers of high-speed cartoning lines running at 200–400 cartons/minute. Above 350 gsm, crease force increases and you risk cracking the board surface on auto-fold lines.

Q2: What is your MOQ and lead time for pharmaceutical folding cartons?
A: Our standard MOQ for pharmaceutical folding cartons is 10,000 units per SKU, which allows us to run a full quality-controlled press sheet with inline vision inspection. Production lead time after sample approval is 25–30 working days. Rush production at 18–20 working days is available for repeat orders with pre-approved artwork.

Q3: Do your pharmaceutical cartons comply with EU Braille requirements?
A: Yes. EU Directive 2004/27/EC mandates Braille on all prescription medicine packaging for EU markets. We verify Braille dot height at 0.2–0.5mm and spacing per EN ISO 17351 on every sample and conduct a 30-unit Braille check per production lot as part of our outgoing QC.

Q4: Can you apply both hot foil stamping and UV spot varnish on a pharmaceutical carton?
A: Yes, we run foil-plus-UV combinations regularly. The key constraint is sequencing: UV spot varnish must be applied after foil stamping, and the UV cure energy must be calibrated to avoid heat transfer that lifts foil edges — we run UV cure at 120–160 mJ/cm² for this combination. Foil coverage above 40% of panel area requires a primer coat to ensure adhesion on SBS.

Q5: What is the most common quality failure you see on pharmaceutical cartons from other suppliers, and how do you prevent it?
A: The most common issue we see when brands switch to us from a previous supplier is barcode degradation — cartons arriving at Grade C or below on ISO/IEC 15416 verification, which fails pharmaceutical line scanners. The root cause is usually dot gain on uncoated or under-coated board. We prevent this by specifying SBS with a minimum CIE brightness of 88% ISO and running 100% inline barcode verification on every pharmaceutical carton job, not just spot checks.

---

Planning a packaging project? Contact our team to request a complimentary specification review and sample quote.